On August 29, 2024 Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, reported that management will participate in the following upcoming investor conferences (Press release, Alector, AUG 29, 2024, View Source [SID1234646193]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Morgan Stanley 22nd Annual Global Healthcare Conference (New York, New York)
Thursday, September 5, 2024, at 7:45 a.m. ET, fireside chat
H.C. Wainwright 26th Annual Global Investment Conference (New York, New York)
Monday, September 9, 2024, at 10:00 a.m. ET, fireside chat
2024 Cantor Global Healthcare Conference (New York, New York)
Tuesday, September 17, 2024, at 9:45 a.m. ET, fireside chat

A webcast of each presentation will be available on the "Events & Presentations" page within the Investors section of the Alector website at View Source Replays of the webcasts will be available on the Alector website for 90 days following the presentation dates.

On August 29, 2024 Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, reported that it will webcast its presentations at three investor conferences in September. The presentations will feature a business overview and update (Press release, Sana Biotechnology, AUG 29, 2024, View Source [SID1234646209]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Sana will present at the Morgan Stanley 22nd Annual Global Healthcare Conference at 11:30 a.m. ET on Wednesday, September 4, 2024.
Sana will present at the 2024 Wells Fargo Healthcare Conference at 3:00 p.m. ET on Thursday, September 5, 2024.
Sana will present at the HC Wainwright 26th Annual Global Investment Conference at 12:30 p.m. ET on Monday, September 9, 2024.

The webcasts will be accessible on the Investor Relations page of Sana’s website at View Source A replay of each presentation will be available at the same location for 30 days following the conference.

On August 29, 2024 Amgen (NASDAQ:AMGN) reported that it will present at the Morgan Stanley 22nd Annual Global Healthcare Conference at 9:15 a.m. ET on Wednesday, Sept. 4, 2024. Robert A. Bradway, chairman and chief executive officer at Amgen, will present at the conference (Press release, Amgen, AUG 29, 2024, View Source [SID1234646194]). The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The webcast, as with other selected presentations regarding developments in Amgen’s business given by management at certain investor and medical conferences, can be found on Amgen’s website, www.amgen.com, under Investors. Information regarding presentation times, webcast availability and webcast links are noted on Amgen’s Investor Relations Events Calendar. The webcast will be archived and available for replay for at least 90 days after the event.

On August 29, 2024 Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultrarare genetic diseases, reported participation in three upcoming investor conferences (Press release, Ultragenyx Pharmaceutical, AUG 29, 2024, View Source [SID1234646211]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Morgan Stanley 22nd Annual Global Healthcare Conference (New York, NY)

Wednesday, September 4, 2024, Emil Kakkis, M.D., Ph.D., CEO and President, will participate in a fireside chat and host 1×1 meetings.
Cantor Global Healthcare Conference (New York, NY)

Tuesday, September 17, 2024, Emil Kakkis and Howard Horn, Chief Financial Officer, will participate in a fireside chat and host 1×1 meetings.
Bank of America Global Healthcare Conference (London, UK)

Wednesday, September 18, 2024, Eric Crombez, M.D., Chief Medical Officer and Joshua Higa, Vice President, Investor Relations, will participate in a fireside chat and host 1×1 meetings.
The live and archived webcast of the fireside chats will be accessible from the company’s website at View Source

On August 29, 2024 BioInvent reported its interim report January-June 2024 (Presentation, BioInvent, AUG 29, 2024, https://www.bioinvent.com/sites/bioinvent/files/pr/20240829-62083804-96f4-43c0-807d-6f2d1876beb7-1.pdf?ts=1724911211 [SID1234646695]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!